Female Sexual Dysfunction Treatment Market 2019 Showing Impressive Growth by 2026

Posted on Oct 11 2019 10:23 AM

"Female Sexual Dysfunction Treatment Market 2019 Fortune Business Insights report presents you analysis of market size, share, and growth, trends, and cost structure, statistical and comprehensive data of the global market."

The increasing incidence of chronic diseases such as kidney problems, diabetes, neurological diseases, and others are driving the global sexual dysfunction treatment market predicts Fortune Business Insights in their new study. The study is titled” Female Sexual Dysfunction Treatment Market Size, Share and Global Trend By Type (Arousal Disorder, Penetration Disorder, Female Orgasmic Disorder), By Therapy (Estrogen Therapy, Androgen Therapy, Others), By Age (25 Years, 25-40 Years, Above 40 Years) and Geography Forecast Till 2026.”. This report focusses on major factors restricting and driving the growth of the female sexual dysfunction treatment market during the forecast period, 2018 to 2026.

Browse Complete Report [email protected] https://www.fortunebusinessinsights.com/industry-reports/female-sexual-dysfunction-treatment-market-100850

As per the report, the age group of 40 years and above is dominating the current female sexual dysfunction treatment market and anticipated to continue doing so in the coming years. This is attributable to the wide adoption of unhealthy lifestyle resulting in hormonal imbalance, further leading to sexual dysfunction.

Some of the Main Key Players Covered in the Female Sexual Dysfunction Treatment Market Report:

  • Apricus Biosciences, Inc.
  • GlaxoSmithKline, plc.
  • Pzer, Inc.
  • AMAG Pharmaceuticals
  • Merck & Co., Inc.
  • Cipla Inc.

As per the report, the age group of 40 years and above is dominating the current female sexual dysfunction treatment market and anticipated to continue doing so in the coming years. This is attributable to the wide adoption of unhealthy lifestyle resulting in hormonal imbalance, further leading to sexual dysfunction.

Get Sample PDF [email protected] https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/female-sexual-dysfunction-treatment-market-100850

Awareness Programs Supported and Conducted by Government to Help Asia Pacific Market Register Faster Growth

Fortune Business Insights predicts North America and Europe  female sexual dysfunction treatment market to exhibit strong growth. This is on account of the lifestyle adopted by its residents and rise in the number of the aging population. Besides this, the adoption of unhealthy lifestyle, alcoholism, and other habits are leading to the prevalence of sexual dysfunction in women. This is likely to remain the same helping both regions continue dominating the market collectively in future.

On the other side, the female sexual dysfunction treatment market in the Asia Pacific is likely to grow at faster rate on account of rising awareness about sexual diseases, and the availability of treatment facilities, especially in developing nation such as China, and India. Additionally, governments are also initiating various awareness programs about female sexual dysfunction and increasing the funds on the betterment of healthcare infrastructure and facilities, and this will help the market in Asia Pacific register faster growth rate in the forecast period.

Key Segmentation of Female Sexual Dysfunction Treatment Market:

By Type

  • Arousal Disorder
  • Penetration Disorder
  • Female Orgasmic Disorder

By Therapy

  • Estrogen Therapy
  • Androgen Therapy

By Age

  • 25 Years
  • 25-40 Years
  • Above 40 Years

By Geography

  • North America (USA and Canada)
  • Europe (UK, Germany, France, Italy, Spain, Scandinavia, and Rest of
  • Europe)
  • Asia Pacic (Japan, China, India, Australia, Southeast Asia, and Rest of Asia
  • Pacic)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC, and Rest of the Middle East &
  • Africa)

Psychological Problems Leading to Sexual Dysfunction in Women

The main reason behind sexual dysfunction is psychological or physical disorders including heart problems and neurological diseases. In addition to this, problems such as hormonal imbalance, diabetes, kidney diseases, liver problem, drug abuse, alcoholism, and others also lead to sexual dysfunction. Psychological problems causing sexual dysfunction include situations such as work-related stress, past trauma, relationship problems, anxiety, and others. All factors mentioned above leads to the prevalence of sexual dysfunction in women and thus boost the global female sexual dysfunction treatment market.

Studies have showed female sexual dysfunction may happen to a woman at any stage of life. Thus, such facts are likely to help the female sexual dysfunction market gain traction in the forecast period.

 On the contrary, lack of awareness about sexual problems and their proper diagnostics, especially in the developing nations, may hamper the market growth. This, accompanied by the lack of standardization in treatment facilities and lack of skilled medical professionals may also cause hinder the female sexual dysfunction market growth in the long run.

New Drug Approvals to Bode Well for Market Players

Companies are focussing on major strategies such as new product launches, company collaborations, and merger and acquisitions for gaining the lion's share in the market. For instance, a new drug application (NDA) of a first-in-class melanocortin-4 receptor called bremelanotide by AMAG Pharmaceuticals was accepted by the Food and Drug Administration (FDA). This drug is meant to treat hypoactive sexual desire disorders (HSDD) among premenopausal women. Such innovations are likely to bode well for the market as well for company portfolio in future.

Some of the companies functioning in the global female sexual dysfunction treatment market are Cipla Inc., Pfizer, Inc., AMAG Pharmaceuticals, Apricus Biosciences, Inc., Merck & Co., Inc., GlaxoSmithKline, plc., and others.

More Trending Topics from Fortune Business Insights:

Nurse Call Systems Market to Exhibit a CAGR of 11.5% | USD 2.79 Billion by 2026

Germany Home Healthcare Market Will Spur Growth at a CAGR of 5.6% to reach USD 4,446.9 Mn by 2026

Next Generation Sequencing Market to Exhibit 22.2% CAGR | USD 31,411.3 Mn by 2026